Abstract
The Ebola virus (EBOV) is a pathogen that causes hemorrhagic fevers in humans. It is most prevalent in Africa, where outbreaks with fatality rates of up to 90% have occurred. It also poses a global threat as infections can be spread rapidly. While it is known that EBOV infections function by inhibiting the immune system, the specific cellular secretion pathway of the virus has not been uncovered. As no treatment for this deadly virus exists, it is important to learn how EBOV co‐opts infected cells in order to pharmacologically target the formation and egress of new virions. VP40, one of the seven structural proteins that EBOV encodes, is essential for initiation of new virion formation at the plasma membrane. In this study, vesicular sedimentation assays were used to better understand the lipid binding properties of VP40. In addition, surface plamon resonance (SPR) was used to determine the binding specificity of the wild type VP40 and mutant VP40 A299W. VP40 WT and VP40 A299W bind phosphatidylserine (PS), a plasma membrane phospholipid, with equal affinity. VP40 is essential for EBOV cellular egress and the mechanisms by which it is targeted to the plasma membrane and subsequently recruits the virus capsid are under further investigation.This research is supported by the NIH (AI081077).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.